News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
25,837 Results
Type
Article (3897)
Company Profile (4)
Press Release (21934)
Multimedia
Podcasts (29)
Webinars (4)
Section
Business (8953)
Career Advice (41)
Deals (1231)
Drug Delivery (19)
Drug Development (4472)
Employer Resources (12)
FDA (714)
Job Trends (1081)
News (15067)
Policy (1568)
Tag
Academia (81)
Accelerated approval (1)
Adcomms (2)
Allergies (2)
Alliances (2277)
ALS (2)
Alzheimer's disease (38)
Antibody-drug conjugate (ADC) (83)
Approvals (721)
Artificial intelligence (25)
Autoimmune disease (11)
Automation (2)
Bankruptcy (9)
Best Places to Work (850)
BIOSECURE Act (7)
Biosimilars (6)
Biotechnology (1)
Bladder cancer (21)
Brain cancer (11)
Breast cancer (69)
Cancer (507)
Cardiovascular disease (40)
Career advice (43)
Career pathing (2)
CAR-T (10)
CDC (14)
Cell therapy (21)
Cervical cancer (6)
Clinical research (3821)
Collaboration (86)
Company closure (2)
Compensation (7)
Complete response letters (7)
COVID-19 (209)
CRISPR (2)
C-suite (85)
Cystic fibrosis (2)
Data (246)
Depression (4)
Dermatology (1)
Diabetes (6)
Diagnostics (96)
Diversity, equity & inclusion (3)
Drug discovery (14)
Drug pricing (49)
Drug shortages (1)
Duchenne muscular dystrophy (6)
Earnings (2301)
Editorial (8)
Employer branding (6)
Employer resources (12)
Events (2519)
Executive appointments (95)
FDA (814)
Funding (52)
Gene editing (8)
Generative AI (4)
Gene therapy (17)
GLP-1 (83)
Government (336)
Grass and pollen (1)
Guidances (8)
Healthcare (482)
HIV (12)
Huntington's disease (2)
IgA nephropathy (3)
Immunology and inflammation (28)
Immuno-oncology (16)
Indications (9)
Infectious disease (239)
Inflammatory bowel disease (9)
Inflation Reduction Act (4)
Influenza (1)
Intellectual property (7)
Interviews (2)
IPO (376)
IRA (12)
Job creations (284)
Job search strategy (40)
JPM (9)
Kidney cancer (6)
Labor market (11)
Layoffs (64)
Leadership (1)
Legal (397)
Liver cancer (7)
Longevity (1)
Lung cancer (115)
Lymphoma (13)
Machine learning (2)
Management (4)
Manufacturing (47)
MASH (6)
Medical device (79)
Medtech (79)
Mergers & acquisitions (897)
Metabolic disorders (51)
mRNA (33)
Multiple sclerosis (14)
Neurodegenerative disease (15)
Neuropsychiatric disorders (9)
Neuroscience (84)
NextGen: Class of 2026 (204)
Non-profit (98)
Now hiring (2)
Obesity (35)
Opinion (37)
Ovarian cancer (22)
Pain (6)
Pancreatic cancer (6)
Parkinson's disease (5)
Patents (19)
Patient recruitment (8)
People (4093)
Pharmaceutical (2)
Pharmacy benefit managers (3)
Phase 1 (1097)
Phase 2 (1714)
Phase 3 (1595)
Pipeline (256)
Policy (61)
Postmarket research (206)
Preclinical (281)
Press Release (2)
Prostate cancer (6)
Psychedelics (9)
Radiopharmaceuticals (17)
Rare diseases (33)
Real estate (206)
Recruiting (4)
Regulatory (1099)
Reports (6)
Research institute (74)
Resumes & cover letters (1)
RNA editing (1)
RSV (17)
Schizophrenia (4)
Series A (15)
Series B (9)
Sickle cell disease (3)
Special edition (7)
Spinal muscular atrophy (4)
Sponsored (2)
Startups (217)
Stomach cancer (9)
Supply chain (7)
Tariffs (23)
The Weekly (27)
Vaccines (155)
Venture capital (14)
Weight loss (31)
Women's health (3)
Worklife (1)
Date
Today (12)
Last 7 days (36)
Last 30 days (95)
Last 365 days (1029)
2026 (297)
2025 (1029)
2024 (1236)
2023 (1322)
2022 (2890)
2021 (2705)
2020 (2222)
2019 (1539)
2018 (1204)
2017 (1326)
2016 (1161)
2015 (1306)
2014 (868)
2013 (725)
2012 (794)
2011 (885)
2010 (818)
Location
Africa (65)
Alabama (4)
Alaska (1)
Arizona (2)
Asia (1590)
Australia (403)
California (227)
Canada (95)
China (110)
Colorado (4)
Connecticut (7)
Delaware (14)
Europe (4410)
Florida (66)
Georgia (2)
Illinois (11)
Indiana (3)
Japan (62)
Kansas (1)
Kentucky (1)
Maryland (55)
Massachusetts (264)
Michigan (1)
Minnesota (3)
Mississippi (1)
Missouri (3)
Montana (1)
Nevada (2)
New Hampshire (5)
New Jersey (301)
New York (89)
North Carolina (15)
Northern California (119)
Ohio (3)
Oregon (1)
Pennsylvania (30)
Rhode Island (4)
South America (61)
Southern California (83)
Tennessee (1)
Texas (28)
United States (1140)
Utah (8)
Virginia (8)
Washington D.C. (5)
Washington State (29)
West Virginia (1)
Wisconsin (3)
25,837 Results for "merck serono".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Lung cancer
Merck’s early PD-1/VEGF data competitive in lung cancer, but Summit ‘looms large’
While Merck’s PD-1/VEGF asset appears to match the performance of Summit Therapeutics’ ivonescimab, the pharma’s Phase 1/2 readout in non-small cell lung cancer still leaves analysts with some questions moving into later-stage development.
April 20, 2026
·
2 min read
·
Tristan Manalac
Kidney cancer
Merck, Eisai’s Keytruda triplet fails to improve survival in kidney cancer
A triplet regimen comprising Merck’s Welireg and PD-1 blockbuster Keytruda and Eisai’s Lenvima flopped in a Phase 3 renal cell carcinoma trial.
April 21, 2026
·
2 min read
·
Tristan Manalac
Cancer
Merck’s PD-1/VEGF data star in stacked lineup of AACR ‘26 data reveals
The Merck update, which will shed light on a $588 million bet to succeed Keytruda, is part of a roster of presentations that could shape the future of ADCs, protein degraders and KRAS-targeted therapies.
April 17, 2026
·
5 min read
·
Nick Paul Taylor
Cardiovascular disease
Merck’s Cholesterol Pill Delivers ‘Antibody-Like Efficacy’ After Earning FDA Voucher
Merck is eyeing a quick review for its lipid-lowering drug candidate enlicitide, which in December was awarded a Commissioner’s National Priority Voucher.
March 31, 2026
·
2 min read
·
Tristan Manalac
Patents
Merck’s Keytruda Likely Has a Few Extra Years of Dominance, With Billions on the Line
Sales of Merck’s longtime oncology blockbuster Keytruda will erode more starkly in about 2033 rather than 2029, predicts Bloomberg Intelligence, translating to some $22 billion more in revenue.
February 24, 2026
·
3 min read
·
Annalee Armstrong
Mergers & acquisitions
Merck Chopped $1B Off Terns’ Offer After Seeing Updated Leukemia Data
Another bidder, which remains unidentified, dropped out of the bidding process. Analysts at William Blair now think it unlikely that another suitor could offer a counter-proposal to Merck’s outstanding $6.7 billion acquisition offer.
April 8, 2026
·
3 min read
·
Tristan Manalac
Mergers & acquisitions
Merck To Buy Terns, ‘Unprecedented’ Leukemia Drug for $6.7B as Keytruda Cliff Looms
Merck’s acquisition of Terns Pharmaceuticals follows other big-ticket purchases, including of Verona Pharma and Cidara Therapeutics, as the pharma prepares for the impending expiration of its blockbuster’s patents.
March 25, 2026
·
3 min read
·
Tristan Manalac
Bladder cancer
Merck, Pfizer’s Drug Combo ‘Rewrites the Standard of Care’ in Bladder Cancer
A combination of Merck’s Keytruda and Pfizer’s Padcev could offer a chemotherapy-free treatment alternative for patients with muscle-invasive bladder cancer, even those eligible for cisplatin treatment.
March 2, 2026
·
2 min read
·
Tristan Manalac
Drug pricing
In Affordability Push, EMD Serono Joins TrumpRx While Roche Launches DTC Program
EMD Serono will offer its fertility treatments on TrumpRx at a steep discount, and Roche’s direct-to-consumer offering will cover its flu pill Xofluza.
October 17, 2025
·
2 min read
·
Tristan Manalac
Cardiovascular disease
Merck Pushes Winrevair Past Dose-Response Doubts Into Pivotal Study for Rare Type of Heart Failure
The lack of a dose-response effect could be due to the high number of dropouts in the higher-dose Winrevair arm and the relatively small study population, a discussant for Merck explained.
March 30, 2026
·
2 min read
·
Tristan Manalac
1 of 2,584
Next
